Y-mAbs Therapeutics IncNASDAQ:YMAB
- LAST PRICE10.5400
- TODAY'S CHANGE (%)0.2400 (2.3301%)
- Bid / Lots10.3200/ 5
- Ask / Lots11.0000/ 1
- Open / Previous Close10.3300 / 10.3000
- Day Range
- 52 Week Range
- Volume272,544
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | YMAB |
|---|---|---|
| 09:32 ET | 1477 | 10.37 |
| 09:35 ET | 2108 | 10.555 |
| 09:37 ET | 1000 | 10.555 |
| 09:39 ET | 500 | 10.555 |
| 09:42 ET | 1600 | 10.54 |
| 09:46 ET | 27416 | 10.555 |
| 09:48 ET | 500 | 10.45 |
| 09:50 ET | 100 | 10.545 |
| 09:51 ET | 959 | 10.54 |
| 09:53 ET | 3570 | 10.375 |
| 09:55 ET | 200 | 10.47 |
| 09:57 ET | 100 | 10.375 |
| 10:00 ET | 100 | 10.43 |
| 10:02 ET | 3300 | 10.49 |
| 10:04 ET | 902 | 10.445 |
| 10:06 ET | 1800 | 10.445 |
| 10:08 ET | 500 | 10.466 |
| 10:09 ET | 3012 | 10.52 |
| 10:11 ET | 603 | 10.535 |
| 10:15 ET | 100 | 10.535 |
| 10:20 ET | 942 | 10.435 |
| 10:22 ET | 100 | 10.53 |
| 10:26 ET | 100 | 10.425 |
| 10:27 ET | 200 | 10.43 |
| 10:29 ET | 364 | 10.42 |
| 10:31 ET | 421 | 10.34 |
| 10:33 ET | 480 | 10.423 |
| 10:36 ET | 778 | 10.48 |
| 10:42 ET | 1042 | 10.55 |
| 10:44 ET | 200 | 10.6 |
| 10:45 ET | 106 | 10.56 |
| 10:47 ET | 480 | 10.575 |
| 10:49 ET | 213 | 10.575 |
| 10:51 ET | 800 | 10.545 |
| 10:56 ET | 100 | 10.55 |
| 11:00 ET | 200 | 10.52 |
| 11:02 ET | 411 | 10.55 |
| 11:03 ET | 2200 | 10.5 |
| 11:05 ET | 200 | 10.5 |
| 11:09 ET | 800 | 10.5 |
| 11:12 ET | 300 | 10.49 |
| 11:14 ET | 100 | 10.5 |
| 11:16 ET | 100 | 10.5 |
| 11:18 ET | 100 | 10.5 |
| 11:21 ET | 200 | 10.465 |
| 11:25 ET | 200 | 10.4817 |
| 11:27 ET | 900 | 10.44 |
| 11:30 ET | 325 | 10.47 |
| 11:34 ET | 400 | 10.44 |
| 11:38 ET | 100 | 10.5 |
| 11:39 ET | 610 | 10.45 |
| 11:43 ET | 200 | 10.45 |
| 11:45 ET | 200 | 10.4 |
| 11:48 ET | 200 | 10.415 |
| 11:50 ET | 300 | 10.425 |
| 11:52 ET | 1500 | 10.37 |
| 11:56 ET | 100 | 10.36 |
| 11:57 ET | 100 | 10.385 |
| 11:59 ET | 411 | 10.36 |
| 12:03 ET | 200 | 10.4 |
| 12:08 ET | 100 | 10.39 |
| 12:12 ET | 600 | 10.405 |
| 12:14 ET | 5452 | 10.56 |
| 12:15 ET | 1600 | 10.58 |
| 12:17 ET | 1000 | 10.73 |
| 12:19 ET | 1003 | 10.72 |
| 12:21 ET | 500 | 10.745 |
| 12:24 ET | 900 | 10.825 |
| 12:26 ET | 579 | 10.815 |
| 12:28 ET | 600 | 10.76 |
| 12:32 ET | 1100 | 10.735 |
| 12:35 ET | 100 | 10.74 |
| 12:37 ET | 200 | 10.72 |
| 12:42 ET | 2797 | 10.77 |
| 12:44 ET | 416 | 10.76 |
| 12:46 ET | 500 | 10.76 |
| 12:48 ET | 500 | 10.76 |
| 12:50 ET | 1029 | 10.82 |
| 12:51 ET | 200 | 10.81 |
| 12:53 ET | 100 | 10.81 |
| 12:57 ET | 483 | 10.81 |
| 01:02 ET | 1200 | 10.81 |
| 01:04 ET | 2400 | 10.74 |
| 01:06 ET | 900 | 10.76 |
| 01:08 ET | 700 | 10.77 |
| 01:09 ET | 500 | 10.8 |
| 01:11 ET | 900 | 10.82 |
| 01:13 ET | 100 | 10.82 |
| 01:15 ET | 1075 | 10.825 |
| 01:18 ET | 100 | 10.825 |
| 01:29 ET | 200 | 10.82 |
| 01:33 ET | 1309 | 10.785 |
| 01:36 ET | 100 | 10.795 |
| 01:38 ET | 100 | 10.75 |
| 01:40 ET | 200 | 10.76 |
| 01:42 ET | 379 | 10.75 |
| 01:44 ET | 400 | 10.75 |
| 01:45 ET | 379 | 10.8 |
| 01:49 ET | 1124 | 10.75 |
| 01:51 ET | 1571 | 10.75 |
| 01:54 ET | 400 | 10.75 |
| 01:56 ET | 202 | 10.75 |
| 01:58 ET | 300 | 10.77 |
| 02:00 ET | 1493 | 10.66 |
| 02:02 ET | 625 | 10.64 |
| 02:03 ET | 4617 | 10.63 |
| 02:07 ET | 400 | 10.74 |
| 02:09 ET | 100 | 10.75 |
| 02:12 ET | 100 | 10.71 |
| 02:14 ET | 1534 | 10.735 |
| 02:16 ET | 300 | 10.735 |
| 02:18 ET | 1373 | 10.74 |
| 02:20 ET | 100 | 10.775 |
| 02:23 ET | 100 | 10.765 |
| 02:25 ET | 100 | 10.74 |
| 02:32 ET | 200 | 10.72 |
| 02:39 ET | 300 | 10.73 |
| 02:41 ET | 700 | 10.72 |
| 02:43 ET | 100 | 10.69 |
| 02:45 ET | 1206 | 10.675 |
| 02:48 ET | 400 | 10.665 |
| 02:50 ET | 100 | 10.65 |
| 02:52 ET | 300 | 10.64 |
| 02:54 ET | 1306 | 10.69 |
| 02:56 ET | 200 | 10.7 |
| 02:57 ET | 480 | 10.71 |
| 02:59 ET | 100 | 10.7 |
| 03:01 ET | 535 | 10.7 |
| 03:03 ET | 1000 | 10.635 |
| 03:06 ET | 1704 | 10.66 |
| 03:10 ET | 600 | 10.64 |
| 03:12 ET | 101 | 10.65 |
| 03:14 ET | 200 | 10.64 |
| 03:15 ET | 1200 | 10.67 |
| 03:17 ET | 303 | 10.67 |
| 03:21 ET | 461 | 10.6 |
| 03:24 ET | 587 | 10.6 |
| 03:26 ET | 9545 | 10.715 |
| 03:28 ET | 1059 | 10.715 |
| 03:30 ET | 402 | 10.715 |
| 03:32 ET | 200 | 10.68 |
| 03:33 ET | 500 | 10.67 |
| 03:35 ET | 924 | 10.68 |
| 03:37 ET | 700 | 10.685 |
| 03:39 ET | 2428 | 10.8 |
| 03:42 ET | 516 | 10.755 |
| 03:44 ET | 525 | 10.74 |
| 03:46 ET | 1600 | 10.735 |
| 03:48 ET | 2723 | 10.795 |
| 03:50 ET | 300 | 10.75 |
| 03:51 ET | 600 | 10.71 |
| 03:53 ET | 1480 | 10.69 |
| 03:55 ET | 1721 | 10.66 |
| 03:57 ET | 5377 | 10.58 |
| 04:00 ET | 58457 | 10.54 |
Today
Dec 5, 2024
DJ Y-mAbs Therapeutics Initiated at Buy by Brookline Capital, from 5:26AM ET on Thursday Dec 05, 2024 by Dow Jones
5:26AM ET on Thursday Dec 05, 2024 by Dow Jones
Nov 27, 2024
Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference, from 7:35AM ET on Wednesday Nov 27, 2024 by Dow Jones
7:35AM ET on Wednesday Nov 27, 2024 by Dow Jones
Nov 18, 2024
DJ Y-mAbs Therapeutics Initiated at Outperform by Oppenheimer, from 8:59AM ET on Monday Nov 18, 2024 by Dow Jones
8:59AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 15, 2024
DJ Y-mAbs Therapeutics Price Target Maintained With a $22.00/Share by HC Wainwright & Co., from 2:23PM ET on Friday Nov 15, 2024 by Dow Jones
2:23PM ET on Friday Nov 15, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Y-mAbs Therapeutics Inc | 472.1M | -19.5x | --- |
Regenxbio Inc | 474.6M | -1.9x | --- |
Chromadex Corp | 513.3M | 355.0x | --- |
Urogen Pharma Ltd | 518.6M | -3.9x | --- |
SAGE Therapeutics Inc | 343.2M | -1.0x | --- |
Codexis Inc | 384.9M | -5.4x | --- |
Company Information
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
Contact Information
- Headquarters
- 230 PARK AVENUE, SUITE 3350NEW YORK, NY, United States 10169
- Phone
- 212-847-9841
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- James Healy
- President, Chief Executive Officer, Director
- Michael Rossi
- Vice Chairman of the Board, Chief Business Officer
- Thomas Gad
- Chief Financial Officer, Treasurer
- Peter Pfreundschuh
- Chief Operating Officer, Senior Vice President
- Joris Wilms
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $472.1M |
|---|---|
Revenue (TTM) | $84.6M |
Shares Outstanding | 44.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.61 |
EPS | $-0.54 |
Book Value | $2.31 |
P/E Ratio | -19.5x |
Price/Sales (TTM) | 5.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -33.66% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
